Techno Trends
Techno Trends includes advancements and innovations in pharmaceutical products and technology from around the world. Additionally, you may keep abreast of any recent advancements in the pharmaceutical industry (product information and technological trends).
XACDURO: Targeted Antibiotic for Acinetobacter in Adult HABP/VABP
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, has introduced XACDURO® (sulbactam for injection; durlobactam for injection) to the U.S. market, making it available for individuals aged 18 and above....
Sandoz Achieves FDA Green Light for Tyruko®- Pioneering Biosimilar for Treating Relapsing Multiple Sclerosis
Sandoz, a prominent player in the global pharmaceutical industry specializing in generic and biosimilar medicines, has announced a significant milestone. The US Food and Drug Administration (FDA) has granted its approval for Tyruko® (natalizumab-sztn), a biosimilar developed in collaboration with Polpharma Biologics....
CyGenica Limited Receives from US FDA for Groundbreaking Drug Conjugate in Glioblastoma Multiforme Therapy
CyGenica Limited, a dynamic biotech startup, has achieved a significant milestone in the battle against Glioblastoma Multiforme (GBM), an aggressive form of brain cancer....
Novel Medication VEOPOZ™ Granted FDA Approval for CHAPLE Disease
Regeneron Pharmaceuticals has received FDA approval for Veopoz™ (pozelimab-bbfg) as a pioneering treatment for CHAPLE disease in both adults and pediatric patients aged one year and older. CHAPLE disease, also known as CD55-deficient protein-losing enteropathy...
Lisata Therapeutics Achieves Orphan Drug Designation from U.S. FDA
Lisata Therapeutics, a clinical-stage pharmaceutical company dedicated to pioneering innovative treatments for advanced solid tumors and other severe illnesses, has announced a significant milestone. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to their lead product candidate, LSTA1, specifically for the treatment of malignant glioma....
FDA Approves TALVEY™: Novel Bispecific for Advanced Multiple Myeloma
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has recently announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to TALVEY™ (talquetamab-tgvs), an innovative bispecific antibody developed for treating adult patients who are facing relapsed or refractory multiple myeloma....
Polpharma Biologics' Natalizumab Biosimilar receives groundbreaking CHMP Assessment for Multiple Sclerosis Treatment
Polpharma Biologics, an international biotech company specializing in biosimilar development and manufacturing, has recently received a positive evaluation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)....
Adcentrx Therapeutics Receives IND Approval for ADRX-0706: A Novel ADC Targeting Nectin-4 in Advanced Solid Tumor Treatment
Adcentrx Therapeutics, a biotechnology company dedicated to advancing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other serious diseases, has announced the clearance of its Investigational New Drug (IND) application for ADRX-0706 by the U.S....
FDA Grants Breakthrough Approval to BioMarin's ROCTAVIAN™, the First Gene Therapy for Severe Hemophilia A in Adults
BioMarin Pharmaceutical Inc., a global biotechnology company, recently announced the approval of their gene therapy called ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) by the United States Food and Drug Administration (FDA)....
FDA Grants Clearance to Poseida Therapeutics' Investigational Dual CAR-T Therapy for B-Cell Cancer
Poseida Therapeutics, a clinical-stage company specializing in cell and gene therapy, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1....
